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Abstract
Rationale, aims and objectives Clinicians are generally advised to consider several risk
factors when evaluating patients’ cardiovascular disease (CVD) risk. Our aim was to study
whether combined assessment of ﬁve traditional risk factors might help doctors demarcate
a relatively distinct and manageable group of high-risk individuals. We selected ﬁve
modiﬁable risk factors and estimated the proportion of a well-deﬁned population with
‘unfavourable’ levels of at least two of them, as deﬁned by four internationally renowned
guidelines. The impact of including so-called ‘prehypertension’among the risk factors was
speciﬁcally addressed, and the results are discussed in a wider perspective.
Material and methods Guideline implementation was modelled on data from a cross-
sectional Norwegian population study comprising 62 104 adults aged 20–79 years (The
Nord-Tröndelag Health Study 1995–7).Total, age- and gender-speciﬁc point prevalences of
individuals with zero, one, two, three or more factors, in addition to established disease,
were calculated.
Results One single CVD risk factor was exhibited by 12.4% of the population; two factors
by 21.5%; and three or more by 49.7%. Established CVD or diabetes mellitus was reported
by 12.5%. In total, 83.7% of the population exhibited a risk or disease proﬁle with at least
two factors, if prehypertension was included.
Conclusions If guideline recommendations are literally applied, as many as 84% of adults
in Norway could exhibit two or more CVD or risk factors and thus be considered in need
of individual, clinical attention. This challenges the widely held presumption that ‘the net
will close’ around a manageable group of individuals-at-risk if several risk factors are
jointly considered. As the ﬁnding of this study arises in one of the world’s most long- and
healthy-living populations, it raises several practical as well as ethical questions.
Introduction
Cardiovascular disease (CVD) is currently the major cause of
death in the Western world, including Europe (see e.g. http://
www.heartcharter.eu). Mortality from CVD has, however,
declined substantially since the 1970s [1], and many Western
populations appear to be undergoing the resolution phase of a
so-called 20th-century epidemic of CVD. This epidemic report-
edly began in the 1930s and peaked in the 1950s and 1960s. The
epidemic’s impact on medical thought and practice has been pro-
found, but still, the reasons behind the rise and fall of CVD in the
20th-century are far from clear [2]. In view of the new ‘epidemics’
of obesity and diabetes, there is a widespread concern that the
burden of CVD will start to rise again.
Large-scale medical searches for factors that could predict
future heart disease began shortly after World War II with the
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tension, hypercholesterolemia and smoking were singled out as the
three most apparent risk factors for ischaemic heart disease. Since
then, increasingly detailed knowledge regarding the impact of
numerous measurable and potentially modiﬁable biological risk
factors and risk markers has been published [2]. Development and
marketing of tolerable and presumably safe antihypertensive and
lipid lowering drugs have contributed much to the immense inter-
est in CVD prevention among researchers and clinicians.
In 1962, theWorld Health Organization published the ﬁrst inter-
national report on the importance of blood pressure control [3].
After this milestone publication, subsequent generations of clini-
cal recommendations and guidelines regarding blood pressure as
well as a steadily increasing number of other measurable risk
factors have been released on both sides of the Atlantic [4–13].
With time, the thresholds for clinical intervention on the basis of
single risk factors have been lowered several times. Redeﬁnition of
a risk factor cut-off point inevitably leads to a corresponding
change in the number of individuals that will be categorized as ‘at
risk’and in need of clinical attention [14,15]. In 2004, our research
group documented that implementation of the 2003 European
guidelines on CVD prevention could label as much as 76% of a
general Norwegian population aged 20 years and older, and 90%
of individuals aged 50 years and older, as having unfavourably
high cholesterol and/or blood pressure levels [15]. Arising in the
context of one of the world’s longest-living and healthiest-living
populations [16], this ﬁnding was highlighted in an editorial in the
British Medical Journal [17]. A heated debate followed on the
BMJ website [17]. Key authors of the European guidelines entered
the debate and stated that the focus on single risk factors repre-
sented a startling lack of understanding, and argued that the Euro-
pean guidelines would not lead to medicalization of whole
populations since CVD risk should in practice be evaluated on the
basis of a combined risk factor estimate. This advice was (and still
is) in line with mainstream clinical recommendations for good
practice [7,9,13]. The crucial question, however, is how well-
combined risk evaluation strategies actually work in practice. Will
they, as intended, aid clinicians to deﬁne a relatively well-
demarcated and manageable high-risk group who can be targeted
for further follow-up?
Formal, combined risk calculators
From the viewpoint of the practicing clinician, there are in prin-
ciple two ways of performing a combined CVD risk evaluation.
The ﬁrst method involves a formal ‘risk prediction algorithm’ or
‘calculator’ developed on the basis of epidemiological outcome
data. The level of a given individual’s conventional risk factors
(modiﬁable, such as blood pressure, cholesterol and smoking; and
unmodiﬁable, i.e. age and gender) will be fed into the algorithm
and result in a computed estimate of risk (for disease events or
mortality). The ﬁrst algorithm of this kind was based on the US
Framingham study [18]. The Framingham model has later been
updated and adjusted for use both in the United States and in
Europe. In 2003, a European risk system called SCORE (System-
atic Coronary Risk Evaluation) was launched, based on data from
12 European cohort studies recruited from the 1970s on [9,19,20].
In 2003 and 2007, European guidelines on CVD prevention based
on the SCORE system have been published [9,12].
Although a combined risk approach may often represent an
adequate, general approach to CVD risk evaluation, the clinical
implementation of combined CVD risk algorithms has encoun-
tered problems. It has been well documented in a variety of
settings that both the US Framingham and the European SCORE
models may lead to signiﬁcant overestimation of risk [9,12,21–
23]. In 2005, our research group went on to document that imple-
mentation of the SCORE risk system, as outlined in the 2003
European guidelines on CVD prevention, could also label a major-
ity of the above-mentioned Norwegian population as in need of
‘maximal clinical attention’ due to high combined risk [21].
The main reason for the risk calculators’ tendency to statisti-
cally overestimate risk is most likely the previously mentioned
epidemiological decline in CVD incidence leading to a so-called
‘retrospective risk bias’[12,21]. To tackle this dilemma, guideline
authors recommend that risk calculators be calibrated against
national data. But even in the presence of mathematically valid
risk calculators, the size of the high-risk group might still be so
large as to represent a major challenge.
Consideration of multiple risk factors
Clinicians who do not have access to a calibrated and validated
risk calculator for use in their local setting are likely to apply a
more straightforward approach to combined risk evaluation. The
typical case would involve an otherwise healthy person who pre-
sents with a moderately increased blood pressure, or a moderately
increased cholesterol. In this situation, the doctor may or should,
according to guidelines, consider the level of other risk factors
before deciding on further action. The presence of more than one
elevated risk factor (beyond the currently recommended cut-off
point) would strengthen the argument for clinical intervention,
while absence of additional risk factors might justify a more
expectant approach.
The aim of the present study was to examine the practical
usefulness of the latter CVD risk evaluation method from a clinical
viewpoint. We selected ﬁve modiﬁable risk factors, and with ref-
erence to recommended cut-off points in four internationally
renowned guidelines, studied what proportions of a given Norwe-
gian population would exhibit ‘unfavourable’levels of at least two
of them. In our analysis, we speciﬁcally addressed the emerging
risk(orliterallypre-risk)factorcalled‘prehypertension’(120–139/
80–89 mmHg) which has been included in some guidelines since
2003 [8]. Other more recent guidelines avoid using this ambigu-
ous, medical term. They label a blood pressure level of 120–129/
80–84 mmHg as ‘normal’, but indicate that it is not optimal. The
level 130–139/85–89 mmHg is termed ‘high normal’ [9,11,13].
Whatever terminology used, blood pressure in the ranges 120–
139/80–89 have attracted increasing attention as a risk factor for
CVD among researchers and clinicians in the ﬁeld of CVD
prevention [24–26].
Materials and methods
Based on data from a large and well-organized Norwegian popu-
lation study: the Nord-Tröndelag Health Study 1995–7 (HUNT 2
study) [27], we estimated the proportions of the population who
would exhibit unfavourable combinations of risk factors, if evalu-
ated according to the following CVD prevention recommenda-
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[7], the European Society of Cardiology [9,12], the UK National
Institute for Clinical Excellence [10] and the US Joint National
Committee (seventh report, JNC 7) [8], respectively. The guide-
lines’ recommended cut-off points are listed in Table 1.
When modelling the implementation of guidelines, we started
by identifying individuals with self-reported myocardial infarc-
tion, stroke, angina pectoris or on-going antihypertensive treat-
ment. Patients with diabetes mellitus (both types I and II) were
also included here, as current guidelines recommend close CVD
surveillance for these patients. We categorized these people as
having ‘established disease’and thus as eligible for clinical atten-
tion irrespective of current risk factor levels. Subsequently, all
remaining individuals were categorized as ‘below’ or ‘above’ the
recommended limits for the following measured and calculated
CVD risk variables: blood pressure, total serum cholesterol, waist
circumference and body mass index (BMI), and daily smoking. A
family history of premature CVD was also considered as a risk
factor.
The HUNT 2 population study
The HUNT 2 study was designed to investigate the signiﬁcance of
biomedical risk factors. Its design and methods have been
described in detail elsewhere [27]. The overall participation rate
in HUNT 2 was 76% among women and 67% among men (for
both sexes combined 20–29 years: 49%; 30–39 years: 68%;
40–49 years: 77%; 50–59 years: 81%; 60–69 years: 86%). The
present study is based on data from all participants aged
20–79 years (in total 62 104 individuals, 29 288 males and 32 816
females; see Table 2). The HUNT 2 population has been consid-
ered relatively representative for the total Norwegian population
regarding demography, socioeconomic factors, morbidity and
mortality [27].
In the HUNT 2 survey, blood pressure was measured on persons
in seated position by specially trained personnel using a Dinamap
845XT based on oscillometry. Cuff size was adjusted after mea-
suring the arm circumference, and blood pressure was recorded as
the mean values of the second and third of three measurements
performed consecutively at the same visit. Total cholesterol was
measured by an enzymatic colorimetric cholesterolesterase
method [27]. Height was measured to the nearest 1.0 cm and
weight to the nearest 0.5 kg and BMI was calculated as kg m-2.
In the present analysis, smoking was deﬁned as daily smoking
of cigarettes, cigars or pipe. Family history of CVD was deﬁned as
ﬁrst-degree relatives (parents or siblings) with myocardial infarc-
tion before the age of 60 or stroke at any age.
For international comparison, prevalence rates were also calcu-
lated according to the European and World age standardization
(Table 3) [28].
The spss statistical package, version 15.0 (SPSS Inc., Chicago,
IL, USA), was used for statistical frequency analyses. All surveys
in HUNT 2 were approved by the Norwegian Data Inspectorate
and the Regional Committee for Ethics in Medical Research.
Results
The prevalence numbers for each separate risk factor is shown in
Table 4. Unfavourably, high blood pressure (including both hyper-
tension and prehypertension) is the single most prevalent risk
factor for which medical attention would be recommended, fol-
lowed by total cholesterol. In many instances, the prevalence of the
risk factors varied signiﬁcantly when calculated according to the
European and World age standardization.
About 98% of the population had at least one of the risk factors
(or established disease conditions) in question. If ‘prehyperten-
sion’ was excluded, and only hypertension was considered, this
number remained almost unchanged, or 95% (Table 4).
Figure 1 illustrates the potential impact of different blood pres-
sure deﬁnitions according to the guidelines studied. Even the
Table 1 Overview of the selected risk factors’ cut-off points in four
clinical guidelines on CVD: the American Heart Association (AHA), Euro-
pean guidelines on CVD prevention in clinical practice (EUR), National
Institute of Clinical Excellence (NICE) and the Seventh Report of the
Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (JNC 7)
Guideline
Regular assessment by
health care providers
Medical treatment or
follow-up by health care
providers
AHA BP  130/80 mmHg BP  140/90 mmHg
BMI  25.0 kg m
-2
Waist circumference
Men >102 cm
Women >88 cm
Smoking
Family history of CVD
EUR Cholesterol  5 mmol L
-1 BP  140/90 mmHg
BMI  25.0 kg m
-2 Cholesterol > 8 mmol L
-1
Waist circumference
Men >102 cm
Women >88 cm
Smoking
Family history of CVD
NICE BP > 140/90 mmHg BP  160/100 mmHg
Smoking
JNC 7 BP  120/80 mmHg BP  140/90 mmHg
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease.
Table 2 Participants in the HUNT 2 (1995–7) study according to age and
gender
Age groups Men Women Total
20–24 1 761 2 156 3 917
25–29 2 163 2 561 4 724
30–34 2 579 2 917 5 496
35–39 2 820 3 207 6 027
40–44 3 161 3 478 6 639
45–49 3 334 3 566 6 900
50–54 3 064 3 314 6 378
55–59 2 333 2 461 4 794
60–64 2 113 2 292 4 405
65–69 2 232 2 418 4 650
70–74 2 134 2 382 4 516
75–79 1 594 2 064 3 658
Total 29 288 32 816 62 104
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>140/90 mmHg versus 140/90 mmHg would affect 0.8–2.5%
of the people within each age group. It is evident that prehyper-
tension is present in a considerable proportion of the population.
The currently recommended blood pressure cut-off points 130/
80 mmHg (by the AHA guidelines) and 120/80 mmHg (by the
JNC 7 guidelines) would have the greatest consequences among
people younger than 50 years.
Figure 2 shows the point prevalence of people at different ages
who are identiﬁed with established CVD, or with three or more,
two, one, or zero of the CVD risk factors in question. After age
standardization (Europe), it turned out that only 3.9% of the total
population would be labelled as free, from both disease and all the
above-mentioned risk factors. One single risk factor was exhibited
by 12.4% of the population; two risk factors by 21.5%; and three
or more factors by 49.7%. Established CVD or diabetes mellitus
was reported by 12.5%. In total, 83.7% of the population exhibited
a risk or disease proﬁle which involved at least two cardiovascular
risk factors.
Discussion
More than eight of 10 Norwegians may exhibit two or more CVD
risk factors – or established disease – and thus be eligible for
targeted clinical attention, if current recommendations are inter-
preted literally. Rather than aiding practicing clinicians to demar-
cate a reasonable large and manageable high-risk group with
respect to further evaluation and follow-up, combination of risk
factors appears to inﬂate the population at risk.
As can be seen from Table 4, prehypertension has a substantial
impact on the population at risk, as long as blood pressure is
considered in isolation. However, this effect almost vanishes when
all ﬁve factors are considered jointly. This means that most people
with prehypertension also exhibit one or more other risk factors,
such as an unfavourably high level of cholesterol.
Table 3 Standardized age distribution of inhabitants in Europe and the
world, as well as age distribution of the Norwegian population in 2005
Age groups European standard World standard Norway
0–4 8 000 12 000 6 277
5–9 7 000 10 000 6 663
10–14 7 000 9 000 6 800
15–19 7 000 9 000 6 275
20–24 7 000 8 000 5 946
25–29 7 000 8 000 6 301
30–34 7 000 6 000 7 411
35–39 7 000 6 000 7 710
40–44 7 000 6 000 7 135
45–49 7 000 6 000 6 896
50–54 7 000 5 000 6 494
55–59 6 000 4 000 6 524
60–64 5 000 4 000 4 855
65–69 4 000 3 000 3 712
70–74 3 000 2 000 3 320
75–79 2 000 1 000 3 053
80–84 1 000 500 2 589
85+ 1 000 500 2 038
Total 100 000 100 000 100 000
The shadowed area refers to the age groups in our study.
Table 4 Prevalence and 95% CIs of CVD and selected CVD risk factors in the HUNT 2 (1995–7) study as well as calculated prevalence according to
the European and World age standardizations
Risk factors and diseases
Prevalence percentage
(absolute numers)
Age standardized prevalence percentage
Number
missing Europe 95% CI World 95% CI
Hypertension* 43.2 (26 687/61 844) 38.6 38.2–38.9 35.2 34.8–35.6 260
Prehypertension
† 37.8 (23 390/61 871) 40.3 40.0–40.7 42.1 41.7–42.5 233
Cholesterol  5 mmol L
-1 75.8 (46 935/61 929) 72.1 71.7–72.5 68.7 68.4–69.1 175
Body fat
BMI = 25.0–29.9 43.3 (26 718/61 667) 42.2 41.8–42.6 41.1 40.7–41.5 437
BMI  30.0 16.6 (10 217/61 667) 15.6 15.3–15.9 14.8 14.5–15.1 437
Waist obesity
‡ 18.4 (11 291/61 320) 16.6 16.4–16.9 15.4 15.1–15.7 784
Smoking 33.7 (18 288/54 244) 33.6 33.2–34.0 33.5 33.1–33.9 7860
Close relatives
§ with CVD 32.7 (17 797/54 437) 30.3 29.9–30.6 28.1 27.7–28.5 7667
Established disease and/or on preventive treatment 15.8 (9 754/61 769) 12.5 12.3–12.8 10.5 10.3–10.8 335
Myocardial infarction 2.9 (1 781/61 847) 2.2 2.1–2.3 1.8 1.7–1.9 257
Stroke 1.6 (1 006/61 804) 1.2 1.1–1.3 1.0 0.9–1.1 300
Angina pectoris 4.4 (2 702/61 801) 3.2 3.1–3.3 2.6 2.5–2.7 303
Diabetes 2.7 (1 653/61 863) 2.1 2.0–2.3 1.8 1.7–2.0 241
Antihypertensive treatment 10.4 (6 421/61 845) 8.3 8.1–8.5 7.0 6.8–7.2 259
One or more of the above 97.6 (60 051/61 522) 97.0 96.9–97.1 96.5 96.3–96.6 582
One or more of the above except prehypertension 94.8 (57 727/60 872) 93.3 93.1–93.5 92.0 91.8–92.2 1232
*Hypertensinon deﬁned as 140/90 mmHg or on antihypertensive treatment.
†Prehypertension deﬁned as blood pressure 120/80–139/89 mmHg without antihypertensive treatment.
‡Waist circumference: men >102 cm, women >88 cm.
§First-degree relatives with a family history of myocardial infarction before the age of 60 or stroke at any time.
BMI, body mass index; CI, conﬁdence interval; CVD, cardiovascular disease.
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present analysis
The HUNT 2 study population is well deﬁned, with high partici-
pation rates, and considered fairly representative for Norway as a
whole. Compared with other European regions, including regions
involved in the MONICAproject (third phase, 1992–4) [29], it did
not differ signiﬁcantly with respect to cholesterol levels and
smoking habits at the time of data collection. Blood pressure levels
were somewhat higher in the HUNT 2 population than in most
comparable countries, yet lower than in Finland. We acknowledge
that since the data collection in 1995–7, changes may have taken
place, both regarding lifestyle and in the distribution of biological
disease risk factors in the Norwegian population [30]. We may
thereby, like many other investigators in the ﬁeld of CVD, be
introducing a certain retrospective risk bias as we apply population
data collected 10 years ago.
With respect to family risk for CVD, the HUNT 2 study enabled
us to identify individuals who reported ﬁrst-degree relative(s) with
premature myocardial infarction. Stroke in close relatives,
however, was in the HUNT 2 study reported without reference to
age. As can be seen from Table 4, this potential source of overes-
timation has only a minor impact on the resulting risk population.
In this paper, we have deliberately chosen to outline the poten-
tial scenario of complete guideline adherence in the area of indi-
vidual CVD risk assessment. We also chose to include medical
surveillance for ‘prehypertension’ in Figs 1 and 2. It can be
argued that most guidelines do not go that far in their recommen-
dations as yet. On the other hand, opinion leaders in the medical
community appear to be on the brink of accepting the idea, not
only of actively monitoring prehypertension, but even to treat
it with drugs [24,25]. As an illustration of the increasing focus
on the subject, one may note that papers with the words
‘prehypertension’/‘prehypertension’ in the title appeared only
sporadically in PubMed until the year 2003 when it suddenly
appeared in the title of four papers. In 2004, the number of pub-
lications rose to 14; in 2006, 41; and 2007 is likely to see a further
increase. It can also be mentioned that Norwegian health authori-
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prescription’ where advice and individual follow-up were indi-
cated even for people with blood pressure in the ‘prehypertensive’
range. It later turned out that the Green prescriptions had low
legitimacy among Norwegian general practitioners [31]. One of
the reasons may be that the target group was so vast. It has been
calculated that literal adherence to the Green prescription initiative
could in fact consume half of all consultations in Norwegian
primary health care [32].
A medical ‘vision zero’?
Disease prevention and health promotion are, and should remain,
central goals of medicine. It is, however, a major challenge to ﬁnd
a reasonable balance between – on the one hand – biological,
speciﬁc and risk-oriented approaches to improving health, and –
on the other – more general and ‘salutogenetic’ approaches [2].
Deﬁnition of relevant and clinically meaningful cut-off levels for
individual risk intervention is crucial in this connection. We
believe that it can be demoralizing and alienating for primary
health care professionals to feel obliged to inform a large majority
of the individuals they serve that their current cardiovascular
health is not ‘good enough’ according to biomedical standards
[32]. The prospect of thus ‘medicalizing’ a large majority of an
adult population such as the one in Norway, with one of the
world’s longest-living and healthy-living populations according to
WHO statistics [1,16], evokes several epistemological and ethical
challenges [15]. Resource allocation and workload are also among
issues that need careful consideration before authoritative clinical
recommendations are launched [2,15,21].
We believe the present study serves as a vivid illustration of a
piecemeal biomedical empirism that may have become both too
good and at the same time not good enough [33–35]. By ‘too
good’, we mean that the statistical impact of traditional, biological
risk factors for CVD has now been investigated so extensively that
almost every citizen can ﬁnd empirical arguments for concern
related to his or her bodily risk proﬁle. By ‘not good enough’, we
mean that a narrow and reductive biological perspective which
labels almost every citizen as in need of personalized, medical
care, may divert both clinicians’ and politicians’ attention away
from more comprehensive, adequate and sustainable scientiﬁc
approaches to population health and disease [2].
As primary health care doctors and researchers in two of the
richest countries in the Western world, we see it as a duty of
the medical community not only to care for the health status of the
localindividualsweserve,butalsotoconsiderourchosenaimsand
means from a global perspective. We are not convinced that the
currenttrendindirectionofanauthoritative‘visionzero’inthearea
of CVD prevention represents realistic and sound medicine [2].
PeterKosso,philosopherofscience,hasarguedthat‘good’science
which really brings humankind forwards tends to have a distinct
aesthetical quality to it [35]. If the ‘ethos’ of scientiﬁcally based
medicine becomes too dominated by surveillance and control of
individual’sisolatedbiologicalfactors,downtothelowestlevelsof
risk, it may lose its appeal as an impressive, human endeavour.
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